Composition for diagnosing liver cancer and methods of diagnosing liver cancer and obtaining information for diagnosing liver cancer

A method of diagnosing liver cancer in a subject, the method comprising:

• contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (TMED2) on the surface of a microvesicle in the sample to provide a mixture of the sample and the substance, wherein the substance is an anti-TMED2 antibody fixed to a solid support, thereby forming a complex between the anti-TMED2 antibody fixed to the solid support and the TMED2 on the surface of the microvesicle;
• separating the complex from the mixture;
• measuring the level of a marker for a microvesicle from the complex in the sample, wherein the marker is a surface protein on the microvesicle selected from the group consisting of CD63, CD83, integrin-beta 1 (ITGB1), CD9, CD36, CD81, EpCAM, caveolin, FasL, HLA-DRA, MUC1, ERBB4, GPER, ERBB2, MLANA, and AMHR2;
• measuring the level of the marker for a microvesicle in a control sample;
• and
• determining that the subject has a liver cancer when the level of the marker for a microvesicle in the sample is greater than that in the control sample,
• wherein the control sample includes a plurality of samples obtained from cirrhosis patients.